Literature DB >> 10852594

Transplantation of autologous and allogeneic bone marrow with liver from a cadaveric donor for primary liver cancer.

O Ringdén1, G Söderdahl, J Mattsson, M Uzunel, M Remberger, P Hentschke, H Hägglund, E Sparrelid, A Elmhorn-Rosenborg, F Duraj, H Zetterquist, B G Ericzon.   

Abstract

BACKGROUND: In histocompatibility mismatched experimental animals, a combination of T-cell-depleted autologous and allogeneic marrow may induce mixed chimerism and tolerance. Patients with large primary liver tumors have a poor outcome. We investigated whether it were possible to induce mixed chimerism and obtain an antitumor effect in a patient with a large primary liver cancer after combined liver and bone marrow transplantation (BMT).
METHODS: A 46-year-old female with a primary non resectable liver cancer received a liver transplant from a cadaveric donor. Subsequently, she was conditioned with 4x2 Gy of total lymphoid irradiation, 120 mg/kg cyclophosphamide, and 7.5 Gy total body irradiation. Twelve days after liver transplantation, she received T-cell-depleted autologous:cadaveric 5/6 antigen HLA-mismatched marrow in a proportion of CD34+ cells of 0.5:3.0x10(6)/kg. Chimerism status was determined with polymerase chain reaction amplification of variable number tandem repeats from DNA obtained from CD3+, CD19+, and CD45+ magnetic-bead-separated cells.
RESULTS: The early posttransplant period was uneventful; liver function was normal and the hematopoietic engraftment of donor and recipient origin was prompt. Alpha-fetoprotein levels dropped from 440 to 35 microg/l. One month after marrow transplantation, donor T-cells decreased markedly. Monoclonal antibody OKT-3 and 10(5)/kg donor T-cells were given. One month later, the patient developed diarrhea and abdominal pain. A colonoscopy showed moderate gastrointestinal acute graft-versus-host disease and a Cryptosporidium infection. Three months after BMT, she became a complete donor chimera. Chimera cells showed little, if any, reactivity in mixed lymphocyte cultures to recipient and donor cells, but reacted to third party. Five months after BMT, she developed progressive Aspergillus fumigatus pneumonia and died. No tumor was found at the autopsy.
CONCLUSION: We obtained mixed donor-recipient hematopoietic chimerism without severe acute graft-versus-host-disease, after combined T-cell depleted autologous and allogeneic BMT and a transplantation of a liver from an HLA-mismatched cadaveric donor. Additional donor T-cells enhanced donor bone marrow engraftment, but rejected the autograft. On the basis of this first attempt, further clinical studies are warranted.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10852594     DOI: 10.1097/00007890-200005270-00012

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  6 in total

1.  Poor immune reconstitution after four or five major HLA antigens mismatched T cell-depleted allogeneic and autologous stem cell transplantation.

Authors:  J Mattsson; M Uzunel; M Remberger; L Tammik; B Omazic; V Levitsky; J Z Zou; P Hentschke; O Ringdén
Journal:  Clin Exp Immunol       Date:  2001-01       Impact factor: 4.330

Review 2.  Microchimerism in promoting graft acceptance in clinical transplantation.

Authors:  James M Mathew; Joseph R Leventhal; Joshua Miller
Journal:  Curr Opin Organ Transplant       Date:  2011-08       Impact factor: 2.640

Review 3.  Graft failure after allogeneic hematopoietic cell transplantation.

Authors:  Jonas Mattsson; Olle Ringdén; Rainer Storb
Journal:  Biol Blood Marrow Transplant       Date:  2008-01       Impact factor: 5.742

Review 4.  Hematopoietic cell transplantation for tolerance induction: animal models to clinical trials.

Authors:  Megan Sykes
Journal:  Transplantation       Date:  2009-02-15       Impact factor: 4.939

5.  The immune properties of mesenchymal stem cells.

Authors:  Marianne Castillo; Katherine Liu; Larrissa Bonilla; Pranela Rameshwar
Journal:  Int J Biomed Sci       Date:  2007-06

Review 6.  Progress in Liver Transplant Tolerance and Tolerance-Inducing Cellular Therapies.

Authors:  Xiaoxiao Du; Sheng Chang; Wenzhi Guo; Shuijun Zhang; Zhonghua Klaus Chen
Journal:  Front Immunol       Date:  2020-06-24       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.